Influenza Activity in the United States
2021 – 2022 Season

Data through the week ending January 8, 2022 (week 1)

https://www.cdc.gov/flu/weekly/index.htm

Influenza Virologic Surveillance – United States,
October 3, 2021 through January 8, 2022

Number of influenza positives = 7,969
Influenza Virologic Surveillance – United States, October 3, 2021, through January 8, 2022

<table>
<thead>
<tr>
<th>Virus Subtype/Lineage</th>
<th>Total No. of Subtype/Lineage Tested</th>
<th>HA Clade</th>
<th>Number (% of subtype/lineage tested)</th>
<th>HA Subclade</th>
<th>Number (% of subtype/lineage tested)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/H1</td>
<td>3</td>
<td>6B.1A</td>
<td>3 (100%)</td>
<td>5a.1</td>
<td>2 (66.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5a.2</td>
<td>1 (33.3%)</td>
</tr>
<tr>
<td>A/H3</td>
<td>324</td>
<td>3C.2a.1b</td>
<td>324 (100%)</td>
<td>1a</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1b</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2a</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2a.1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2a.2</td>
<td>323 (99.7%)</td>
</tr>
<tr>
<td>B/Victoria</td>
<td>20</td>
<td>V1A</td>
<td>20 (100%)</td>
<td>V1A</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>V1A.1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>V1A.3</td>
<td>11 (85%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>V1A.3a</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>V1A.3a.1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>V1A.3a.2</td>
<td>9 (45%)</td>
</tr>
<tr>
<td>B/Yamagata</td>
<td>0</td>
<td>Y3</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Antiviral Resistance**
- Oseltamivir, Peramivir, Zanamivir
  - 349 tested
  - No reduced inhibition
- Baloxavir
  - 344 tested
  - No decreased susceptibility

Outpatient Visits for Respiratory Illness, Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)

*This system monitors visits for respiratory illness that includes fever plus cough or sore throat (referred to as ILI) not laboratory confirmed influenza, and may capture patient visits due to other respiratory pathogens that cause similar symptoms.*
ILI Activity Level, Determined by Data Reported to ILINet
Week ending January 8, 2022 (Week 1)

*This system monitors visits for ILI (fever and cough or sore throat), not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.

Percent of Long-Term Care Facilities (LTCF) with at least One Confirmed Influenza Case among Residents, Reported to CDC National Healthcare Safety Network (NHSN), National Summary, October 4, 2021 – January 9, 2022
Influenza Hospitalizations
United States

Influenza Hospital Admissions Reported to HHS Protect
National Summary
October 3, 2021 – January 8, 2022

FluSurv-NET
Cumulative rate of Laboratory-Confirmed influenza hospitalizations among cases of all ages, 2015-16 to 2021-22, MMWR Week 1

Influenza-Related Mortality
United States

Pneumonia, Influenza, and COVID-19 Mortality from
the National Center for Health Statistics Mortality Surveillance System
Data as of January 13, 2022

Influenza-Associated Pediatric Deaths
by Week of Death, 2018-2019 season to 2021-2022 season

*In this figure, cumulative rates for all seasons prior to the 2021-22 season reflect an all-seasons rate. For the 2021-22 season, rates for those hospital admissions are subject to reporting delays. As hospitalization data are updated each week, prior year counts and rates are updated accordingly.
Summary

- Influenza activity declined slightly during the 1st week of January but remains elevated and is expected to continue for several more weeks.
  - Percent of specimens testing positive for influenza.
  - % of outpatient visits for respiratory illness
  - Hospital admissions for influenza reported to HHS Protect

- Majority of viruses detected are A(H3N2).
  - Most are genetically closely related to the vaccine virus but have some antigenic differences
  - No antiviral resistant viruses identified

- Cumulative influenza associated hospitalization rate (FluSurvNet) as of week 1 is -
  - Lower the rate seen at this time during the 4 seasons preceding the COVID-19 pandemic.
  - Slightly higher than the rate at this point in the 2015-2016 season

- It’s not too late to get your flu vaccine.
Additional Information

Influenza Activity
- FluView
  - https://www.cdc.gov/flu/weekly/index
- FluView Interactive
  - https://www.cdc.gov/flu/weekly/fluviewinteractive.htm
- WHO's FluNet
  - https://www.who.int/tools/flunet

Other Respiratory Virus Activity
- COVID Data Tracker Weekly Review
- COVID Data Tracker
  - https://covid.cdc.gov/covid-data-tracker/#datatracker-home
- National Respiratory Virus Surveillance System (NREVSS)
  - https://www.cdc.gov/surveillance/nrevss/index.html